Applied Clinical Trials
Perhaps few issues elicit more interest in clinical trial agreements (clinical grants) than the overhead portion of the contract. Clinical trial agreements typically have three parts: procedures, nonprocedures, and overhead.
Perhaps few issues elicit more interest in clinical trial agreements (clinical grants) than the overhead portion of the contract. Clinical trial agreements typically have three parts: procedures, nonprocedures, and overhead.
Procedures are those medical activities directly related to the protocol that may range from a blood draw to something far more complex. Nonprocedures include an equally broad range of activities, such as study coordinator time, facility charges, patient reimbursement, and meals.
Overheads are indirect institutional costs allocated to individual departments and their programs. These indirect costs can include such illustrative items as costs of the institution's general management, building maintenance, general administration, and in some cases, general marketing efforts.
Here we report U.S. overhead rates. Few pharmaceutical companies are willing to pay overhead costs to office-based investigators. However, most clinical trial agreements with institutions include an overhead figure.
Clinical grant data in GrantPlan from companies conducting 76% of all clinical studies demonstrate that, in general, overheads at academic medical centers are slightly higher than at other institutions.
Instiutions vs Actual Agreements in U.S.-Based Overhead Figures
Particularly noteworthy though is the significant difference between the overhead rate reported by the institution, frequently used as the starting point in negotiations, and the actual amount accepted in the contract by the institution.—TTC (For more information, please contact help@ttc-llc.com.)
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.